HBB gene editing therapy (Tessera Therapeutics/Boston Children's Hospital)

N/A

Report date: 2025/06/11 11:02:36

Base Information

Drug NameHBB gene editing therapy (Tessera Therapeutics/Boston Children's Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionHemoglobin beta chain modulators
TargetsHemoglobin beta chain
Therapy Area/IndicationsAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe Children's Hospital Corp
China Registration ClassN/A

Develop Information

Active CompaniesThe Children's Hospital CorpTessera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAnemia, Sickle Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A